Strata Critical Medical (SRTA) Cash & Current Investments (2019 - 2026)

Strata Critical Medical (SRTA) has 8 years of Cash & Current Investments data on file, last reported at $58.8 million in Q1 2026.

• Quarterly Cash & Current Investments fell 51.01% year-over-year to $58.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.8 million (down 51.01% YoY) and the FY2025 annual result came in at $61.2 million, down 50.95% from the prior year.
• Cash & Current Investments declined to $58.8 million in Q1 2026 per SRTA's latest filing, from $61.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $269.1 million in Q1 2022 and bottomed at $53.4 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $142.0 million (2024), against an average of $147.1 million.
• The widest annual swing landed in 2022, when Cash & Current Investments surged 3482.16%; it then sank 60.81% in 2025.
• Tracing SRTA's Cash & Current Investments over 5 years: stood at $153.8 million in 2022, then dropped by 9.37% to $139.4 million in 2023, then dropped by 10.46% to $124.8 million in 2024, then sank by 50.95% to $61.2 million in 2025, then slipped by 3.99% to $58.8 million in 2026.
• Per Business Quant, the three latest SRTA Cash & Current Investments figures stand at $58.8 million (Q1 2026), $61.2 million (Q4 2025), and $53.4 million (Q3 2025).

Peer Comparison